VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity ... ( SAN FRANCISCO Aug. 12 /- VIA Phar...)

VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference

Date:8/12/2008

SAN FRANCISCO, Aug. 12 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that James G. Stewart, senior vice president and chief financial officer of VIA, will present a company update at the Fourth Annual Noble Financial Equity Conference at 8:00 a.m. PT on Tuesday, August 19, 2008 at the Loews Lake Las Vegas Resort in Nevada.

Interested parties may access a live webcast including a virtual slide presentation from the investor section of the VIA website, http://www.viapharmaceuticals.com. A replay will be archived on the VIA website for at least one week following the presentation.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.

About Noble Financial

Noble Financial is a privately-held, full-service capital markets firm driven by what is often overlooked by other firms -- uncovering the value embedded in the orphaned, undiscovered or misunderstood company. The company focuses on converting
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs

Post Your Comments:

VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity ...( SAN FRANCISCO Aug. 12 /- VIA Phar...)